NFKB1 and neoplasm: While NF-κB signalling is constitutively active, most ABC DLBCLs carry either inactivating point mutations, deletions or epigenetic silencing of the PRDM1 gene, and consequently tumour cells are driven to accumulate at the plasmablast stage [91–93].